Abstract
Background: Pancreatic adenocarcinoma often presents with advanced, unresectable or metastatic disease leading to a poor prognosis. Liquid biopsy by circulating tumor DNA (ctDNA) is becoming an important noninvasive diagnostic tool for patients with pancreatic cancer. The purpose of our study was to characterize mutational status of patients with metastatic or recurrent pancreatic adenocarcinoma and investigate the feasibility of obtaining ctDNA routinely for patients in the clinical setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: HPB : the official journal of the International Hepato Pancreato Biliary Association
Paper Title
Journal
Date
